Abstract | OBJECTIVES: BACKGROUND: METHODS: This is a prospective, randomized, double-blind, placebo-controlled study. Fifty patients with recurrent vasovagal syncope were included (at least two episodes in the last year). A baseline tilt test was performed. Twenty patients (40%) had a positive tilt test. Intravenous atenolol prevented a second positive tilt in five patients. The patients were randomized to receive either atenolol or a placebo (26 patients atenolol 50 mg/day, 24 patients placebo). The follow-up procedure lasted one year. The primary end point of the study was the time to first recurrence of syncope. RESULTS: In the intention-to-treat analysis, the group treated with atenolol had a similar number of patients with recurrent syncopal episodes as the placebo group. The Kaplan-Meier actuarial estimates of time to first syncopal recurrence showed that the probability of remaining free of syncope drops similarly in both groups and that there was no statistical difference between both curves (patients treated with atenolol vs. the placebo) with a log-rank test p value of 0.4517. CONCLUSIONS:
|
Authors | A H Madrid, J Ortega, J G Rebollo, J G Manzano, J G Segovia, A Sánchez, G Peña, C Moro |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 37
Issue 2
Pg. 554-9
(Feb 2001)
ISSN: 0735-1097 [Print] United States |
PMID | 11216978
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Atenolol
|
Topics |
- Adolescent
- Adrenergic beta-Antagonists
(administration & dosage)
- Adult
- Aged
- Atenolol
(administration & dosage, adverse effects)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Prospective Studies
- Recurrence
- Syncope, Vasovagal
(etiology, prevention & control)
- Tilt-Table Test
- Treatment Failure
|